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Neutralisation assays are crucial tools to quantify the presence of functional neutralising antibodies in 
serum samples. Since the SARS-CoV-2 virus (the causative agent of COVID-19) is designated as a 
category 3 biosafety level pathogen, pseudotyped viruses bearing the SARS-CoV-2 spike protein 
permit extensive and widespread serum/plasma screening in a BSL 2 laboratory. These assays can be 
used to assess viral tropism, vaccine immunogenicity, efficacy of antiviral compounds (incl. 
therapeutic mAbs) and serosurveillance studies. In this article, we highlight approaches to SARS-CoV-
2 viral pseudotyping, its practicality, and utility in increasing our understanding of neutralising 
antibodies against SARS-CoV-2.
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Pseudotyped viruses (PV) are an alternative to using wild-type viruses for investigating viral entry and 
tropism. The structural core of one virus is used with the surface glycoprotein(s) of another virus, 
greatly reducing the risk associated with handling the wild-type virus and thus removing the 
requirement for high-containment laboratories. Several types of viral cores are used for generating 
PVs such as murine leukaemia virus (MLV), vesicular stomatitis virus (VSV) and, human 
immunodeficiency virus (HIV), all of which have been described previously 1–5. The core of lentiviral 
PVs contain a retroviral vector with a reporter that, upon transduction of target host cells, is integrated 
into the cellular genome and expressed. A luciferase or a fluorescent protein (GFP) is typically used as 
the reporter gene, although colorimetric methods of assay readout exist, which would negate the 
need for expensive laboratory hardware 6,7 . It is worth mentioning that due to the incorporation of 
only the viral surface protein (such as Spike), this system is not able to measure the efficacy of 
neutralisation to other structural viral proteins, since they are not incorporated into the pseudotype 
viruses.
Typical PV generation and titration can be carried out within a two-week timeframe and may be 
readily scaled up to produce large volumes of virus. Storage is recommended   at -80°C, or -20°C for a 
short period of time with little loss of titre, and freeze thaws are preferably kept to a minimum, though 
some pseudotyped viruses may not lose much infectivity even after three freeze thaw cycles 8,9 . 
Various methodologies are publicly available that describe in detail the steps required to generate 
SARS-CoV-2 PVs 9–12. The PV neutralization assay is typically carried out in 96-well plates, whereby 
serum samples are serially diluted and then incubated with a fixed amount of SARS- CoV-2 PVs to allow 
any neutralising antibodies to bind to the Spike (S). Cells naturally expressing the ACE2 receptor and 
the transmembrane serine protease 2 (TMPRSS2) are then added to the plates and incubated for 48-
72 hours otherwise co-transfection of ACE2 and TMPRSS2 plasmids can be carried out to render cells 
such as HEK 293T, and HeLa permissive to infection. If the PVs contain a luciferase reporter, then cells 
are lysed, and luciferase reporter expression is quantified using a luminometer. For GFP-based assays 
the GFP positive cells are counted at each dilution to determine the percentage of neutralisation, using 
a fluorescent microscope or a flow cytometer.
The benefits of using a SARS-CoV-2 PV aside from the enhanced biosafety, is that PV neutralization 
assay screening is highly serum sparing, with as little as 2µL per sample required, and that the assay 
itself is based on the spike S protein being the only CoV antigen in the system, therefore validating  
antibody-receptor binding and neutralisation. Whilst it is true that ELISA assays can be used to detect 
presence of antibodies in response to viral infection, the system itself specifically detects antibody 
binding to the viral protein, but it does not measure whether this interaction results in neutralisation, 
though recently next-generation kits have been developed to provide that level of information 13–15. 
Typically, an initial screening would start with ELISA to detect serum samples with antibodies, followed 
by a PV neutralisation assay (PVNA), which would then provide information on antibody 
neutralisation. PVNAs have been shown to correlate broadly with wild-type virus neutralisation assays 
2,12,16,17. 
Furthermore, generating mutant spike protein can be done readily by site-directed mutagenesis, 
allowing to produce SARS-CoV-2 PVs bearing mutants that may be in circulation (such as the variants 
of concern for SARS-CoV-2), or to evaluate the importance of specific amino acids on receptor binding 
and entry 18–20. The relative ease and short time frame involved in generating single-point mutations 
allows for the rapid screening of key sites and highlights the malleability of pseudotyped viruses and 
their use for investigating variants in circulation 21–23. It is for these reasons that PVNA are considered 
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Many research reports have incorporated PVNA to detect the presence of neutralising antibodies 
against SARS-CoV-2. The verification of the first human monoclonal antibody that neutralises both 
SARS-CoV-1 and SARS-CoV-2, 47D11, was assessed using PVNAs 24. This particular study was 
illuminating as 47D11 did not prevent Spike binding to ACE2, suggesting an unknown mechanism for 
neutralisation.  Nevertheless, strong cross-neutralisation activity was detected in both PVNAs and 
wild-type virus assays, even though 47D11 does not compromise SARS-CoV-2 spike-ACE2 receptor 
binding. This highlights the strengths of using PVNA, as it can detect neutralising activity of antibodies 
that do not necessary prevent virus-host receptor binding. In another study, authors examined plasma 
samples from patients that had previously travelled from Wuhan to Shenzhen, China, during the 
outbreak using pseudotyped HIV particles with either SARS-CoV-1, SARS-CoV-2, or MERS-CoV 25. Some 
of the patients in this study comprised a family cluster, including the first documented case of human 
to human transmission in Shenzhen 26. Neutralising antibody levels varied between patients, and there 
was little cross-neutralisation between the different PVs, suggesting that the RBDs between SARS-
CoV-1 and MERS-CoV are immunologically distinct. The authors had additionally compared the 
antibody neutralisation results using wild-type virus, which was consistent with the PV assay data. A 
study conducted early during the outbreak at a children’s hospital in Seattle, USA had used PV to 
screen for neutralising antibodies 27. Overall, ten seropositive samples had SARS-CoV-2 neutralising 
antibodies, and seven of the seropositive samples were collected from six children who had never 
tested positive for SARS-CoV-2. We found this to be a strong example of how effective PVNAs can be 
as a serological screening tool to detect individuals carrying neutralising antibodies to SARS-CoV-2 
despite testing negative by PCR. This approach of using PVs as a screening tool can be scaled up as 
part of larger serological surveillance studies 28.
PVNA can also be used to measure neutralising antibody responses in patients with varying severity 
of disease 29,30. Sera from recovered COVID-19 patients from a hospital in Guangzhou, China 
categorised as severe, moderate, and mild, were subjected to PVNAs 31. Within the study, 
asymptomatic sera from patients from Chongqing, China, were also included. The results showed a 
correlation between serum neutralisation capacity and disease severity, whereby high severity had 
most neutralising activity. The asymptomatic samples however showed no ability to neutralise PV 
activity, despite detection of RBD-binding antibodies by ELISA. The pseudotyped nAb assay results 
were then confirmed with wild-type virus experiments. This highlights the strengths of using PVs as a 
surrogate virus for neutralisation assays. Studies have also incorporated PVNAs as part of longitudinal 
studies on antibody responses. One study in the UK investigated antibody responses in COVID-19 
positive patients that were categorised by a severity score ranging from 0; asymptomatic, to 5; 
requirement for extracorporeal membrane oxygenation 32. The pseudotyped nAb assays was able to 
reveal that disease severity enhanced the magnitude of neutralising antibody response and the 
authors were able to monitor the neutralisation response in samples collected over 50 days post onset 
of symptoms. Similar longitudinal studies also reported comparable findings using either PVNAs or 
wild-type virus, which provide insight into the kinetics of the immune response, starting at onset of 
infection with follow up bleeds over time  33,34.
Due to the urgent need for a suite of effective vaccines to protect individuals globally against SARS-
CoV-2, significant developments are being made, and many published reports have also incorporated 
PVNA as part of the toolbox to investigate antibody responses post immunisation in both human and 
animal models35,36. For example, in the phase 1 trial of the mRNA-1273 candidate vaccine, PVNAs were 
employed before and after each round of vaccination 37. PVNAs revealed modest antibody responses 
after the first round of vaccination, followed by a robust antibody response after the second round of 
vaccination. Similarly, another study investigating humoral immune responses in mice after initial 
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antibodies in the sera 38. Another investigation developed a prototype DNA vaccine, which was tested 
in rhesus macaques. The PVNAs revealed strong inhibition by the antibodies in the sera, similar to the 
levels observed in patients that recover from SARS-CoV-2, which was verified by ELISA and wild-type 
virus 39. An investigation to assess effectiveness of the immune response after a second infection in 
rhesus macaques had used both PVNAs and wild-type viral neutralisation assays, of which both 
revealed that the second challenge resulted in significant decrease of viral load compared to the initial 
viral infection 40.
Ongoing studies are aiming to use PVNAs to address a key question; what are the immune correlates 
of protection? Currently the World Health Organisation and National Institute for Biological Standards 
and Control (NIBSC) have developed a serological standard in order to allow studies to report antibody 
responses in international units, which would provide valuable insight into what constitutes a 
protective immune response in individuals 41. In conclusion, we believe that pseudotyped viruses are 
a simple and valuable tool to investigate the presence of neutralising antibodies in serum samples 
from animal models and humans. These assays can be scaled to allow high-throughput screening and 
are safe to carry out in BSL-2 laboratories.
Data availability: There is no data associated with this review article
Funding: The Temperton group is funded by the Wellcome Trust (GB-CHC-210183), the MRC 
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